Metformin plus targeted lung cancer drugs for EGFR-mutated cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 3 study tests whether adding metformin to standard targeted medicines (tyrosine kinase inhibitors) helps people with EGFR-mutated non-small cell lung cancer. It’s meant for people who haven’t already had EGFR-targeted treatment and who have healthy enough labs and organs to safely take the study medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have non-small cell lung cancer that is stage IIIB to IV and confirmed by biopsy/pathology
- Have EGFR mutation that makes the cancer sensitive to EGFR-targeted drugs (a “sensitizing” mutation)
- Have measurable cancer on scans (so doctors can track changes during treatment)
- Be age 18 or older, with an OK activity level (ECOG 0–2) and at least 12 weeks of expected lifespan
- Not have taken any EGFR-targeted medicine before (chemotherapy before is allowed if stopped at least 6 months ago)
- Be able to take pills, and have required blood tests and organ function (kidney, liver, and blood counts) within study limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This trial tests a combination of two targeted drugs (DZD9008 and AZD4205) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a new targeted therapy (limertinib) combined with standard chemotherapy (carboplatin and etoposide) for people whose EGFR-positive lung cancer has transformed into small cell lung cancer after failing an EGFR inhibitor. The goal is to see if this combination can slow the cancer and help you live longer.
This study tests a combination of two targeted therapies for non-small cell lung cancer that has continued to grow despite previous EGFR-targeted treatment. It aims to see if adding gumarontinib (a MET inhibitor) to another EGFR-targeted drug can control the cancer for longer.
This trial tests a combination of two drugs—nintedanib and an EGFR inhibitor—for people with EGFR-mutated non-small cell lung cancer whose cancer has stopped responding to their first EGFR inhibitor treatment. The goal is to see if adding nintedanib can help control the cancer again.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.